De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.3111/13696998.2013.839948

Indexing Status
Subject indexing assigned by NLM

MeSH
Antifungal Agents /administration & dosage /economics /therapeutic use; Candidiasis /drug therapy /economics /mortality; Cost-Benefit Analysis; Decision Support Techniques; Echinocandins /administration & dosage /economics /therapeutic use; Fluconazole /economics /therapeutic use; Health Services /economics /utilization; Humans; Life Expectancy; Lipopeptides /administration & dosage /economics /therapeutic use; Microbial Sensitivity Tests; Quality-Adjusted Life Years

AccessionNumber
22013049632

Date bibliographic record published
15/07/2014